AngioDynamics Inc. (NASDAQ:ANGO) shares traded up 4.7% during trading on Wednesday . The company traded as high as $14.73 and last traded at $14.49, with a volume of 149,799 shares changing hands. The stock had previously closed at $13.84.

A number of research analysts have recently commented on the company. Zacks Investment Research upgraded AngioDynamics from a “sell” rating to a “hold” rating in a research note on Wednesday, June 8th. KeyCorp dropped their price target on AngioDynamics from $17.00 to $16.00 and set an “overweight” rating for the company in a research note on Friday, April 8th. Piper Jaffray Cos. initiated coverage on AngioDynamics in a research report on Friday, April 8th. They set a “neutral” rating and a $12.00 target price for the company. Finally, Canaccord Genuity lowered AngioDynamics from a “buy” rating to a “hold” rating and lowered their target price for the stock from $14.50 to $13.00 in a research report on Tuesday, April 5th. Five analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $14.10.

The stock has a 50-day moving average of $12.98 and a 200 day moving average of $11.86. The company’s market capitalization is $521.26 million.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings results on Thursday, April 7th. The company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of $0.14 by $0.01. The firm had revenue of $87.40 million for the quarter. During the same period in the prior year, the business earned $0.12 EPS. AngioDynamics’s quarterly revenue was up .9% on a year-over-year basis. On average, equities research analysts anticipate that AngioDynamics Inc. will post $0.56 earnings per share for the current year.

In related news, VP Charles R. Greiner sold 3,508 shares of the company’s stock in a transaction on Friday, May 6th. The shares were sold at an average price of $12.31, for a total value of $43,183.48. Following the completion of the transaction, the vice president now directly owns 20,910 shares in the company, valued at $257,402.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Stephen A. Trowbridge sold 12,940 shares of the company’s stock in a transaction on Monday, April 25th. The stock was sold at an average price of $12.30, for a total transaction of $159,162.00. Following the completion of the transaction, the senior vice president now owns 32,469 shares of the company’s stock, valued at $399,368.70. The disclosure for this sale can be found here.

A number of hedge funds and institutional investors recently made changes to their positions in ANGO. Lapides Asset Management LLC raised its position in shares of AngioDynamics by 1.2% in the fourth quarter. Lapides Asset Management LLC now owns 700,500 shares of the company’s stock valued at $8,504,000 after buying an additional 8,400 shares during the period. Royce & Associates LLC raised its position in shares of AngioDynamics by 19.0% in the fourth quarter. Royce & Associates LLC now owns 640,801 shares of the company’s stock valued at $7,779,000 after buying an additional 102,098 shares during the period. Principal Financial Group Inc. raised its position in shares of AngioDynamics by 5.2% in the fourth quarter. Principal Financial Group Inc. now owns 174,319 shares of the company’s stock valued at $2,116,000 after buying an additional 8,640 shares during the period. Whitebox Advisors LLC bought a new position in shares of AngioDynamics during the fourth quarter valued at about $1,384,000. Finally, Morgan Stanley raised its position in shares of AngioDynamics by 6.2% in the fourth quarter. Morgan Stanley now owns 98,634 shares of the company’s stock valued at $1,198,000 after buying an additional 5,728 shares during the period.

AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease, and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.